FDORA gave accelerated approval an exit clock

This blog has already drawn the line between a status that buys speed and one that buys approval, in breakthrough designation’s speed without an approval, and the line between a post-marketing commitment FDA can require and one a sponsor only promises, in a PMR that’s required against a PMC that’s only promised. Accelerated approval sits at the intersection of both lines: it trades a confirmed clinical benefit for a predicted one, and for two decades the predicted side of that trade had no reliable way back out when the prediction didn’t hold. A 2022 statute finally built one.

The approval is conditional on a prediction, not a result

21 CFR Part 314 Subpart H lets FDA approve a drug for a serious condition on a surrogate or intermediate clinical endpoint that’s reasonably likely to predict clinical benefit, rather than waiting for the clinical benefit itself to show up in the trial data; 21 CFR Part 601 Subpart E does the same for biologics. The trade only works because the statute attaches a condition to it: the sponsor has to run a confirmatory trial after approval to verify the clinical benefit the surrogate endpoint only predicted. An accelerated approval that never gets its confirmatory trial finished is a prediction FDA is still waiting to find out about.

For two decades, withdrawing one meant a hearing most sponsors could stall

Before December 2022, withdrawing an accelerated approval when a confirmatory trial failed — or never happened — ran through the Act’s general withdrawal procedure, which gave the sponsor a right to a formal evidentiary hearing before FDA could act. Few sponsors contested a withdrawal outright, but the hearing right carried no statutory deadline of its own, and the process could still run for years once a sponsor did contest it, with the product staying on the market while it ran.

Section 3210 rewrote the exit, not the entry

Section 3210 of the Food and Drug Omnibus Reform Act of 2022 — enacted December 29, 2022 as part of the Consolidated Appropriations Act, 2023 — amended 21 U.S.C. 356(c) to give FDA a faster, more structured way to withdraw an accelerated approval: notice to the sponsor with a public explanation of the grounds, an opportunity for the sponsor to request a meeting and submit a written appeal, and — where an advisory committee already reviewed the drug’s accelerated approval — no requirement to convene a second one. FDA still has to let the sponsor respond before withdrawing; FDORA shortened and structured that response rather than removing it.

The same section front-loaded what used to be an afterthought

FDORA also gave FDA the authority to require that a confirmatory trial be underway before approval, or within a specified time after it, rather than leaving the trial’s start date to the sponsor’s own schedule once approval was already granted. FDA now has to specify the trial’s conditions — enrollment targets, milestones, the protocol itself — no later than the approval date, and if FDA decides not to require a post-approval trial at all, it has to publish its reasoning for skipping one. A sponsor also owes FDA a progress report on a required confirmatory trial roughly every 180 days, and FDA has to post that progress publicly rather than holding it inside the application’s own non-public file.

The guidance is still catching up to the statute

FDORA set a mid-2024 deadline for FDA to issue implementing guidance, and FDA did not meet it on every provision; coverage of the expedited withdrawal procedure has moved faster than coverage of the trial-underway requirement. A tracker built against the statute’s own text, rather than against whichever guidance happens to exist on the day it’s built, is the only way to stay current while FDA’s guidance catches up piece by piece.

Where this meets the file

An accelerated-approval tracker that records a confirmatory trial’s status as a single open-or-closed field has nowhere to put the fact that now actually matters: whether that trial was required to be underway at approval, the 180-day progress-report clock it’s running against, and whether FDA has published its own rationale for whatever trial condition it set. A post-marketing tracking template that keeps those three fields separate from the trial’s general status is previewed in the launch catalog alongside this week’s other drug-lifecycle templates. If your program tracks a confirmatory trial’s exposure differently, the shelf takes that correction directly.